Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.

Abstract: The embodiment of the present application discloses a 3D interaction method, device, computer equipment and storage medium. The method comprises the steps of acquiring motion trail data of a gesture; identifying hand joint position information of the gesture based on the motion trail data; identifying a trigger as a corresponding trigger gesture to realize an interaction operation in an interactive interface based on stay or movement of the hand joint position information within a preset time, wherein the gesture is within an acquisition scope of non-contact gesture control equipment. Thus, the usability of non-contact gesture recognition is improved and the misjudgment rate is reduced with higher operational fluency, better compatibility and improved user experience.

Abstract: Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structure.

Abstract: Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same.

Abstract: The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.

Abstract: This combined dehydration device continuously supplies primarily dehydrated sludge to a sludge supply part, the combined dehydration device including: a multiple rotary disk-type solid-liquid separation device and an electroosmosis dehydration device. In the multiple rotary disk-type solid-liquid separation device, a plurality of rotary shafts in which a plurality of rotary disks are fitted and mounted are arranged from the upstream side toward the downstream side and pivotally supported; while the rotary disks are rotated, water to be treated including sludge is supplied from over the rotary disks at the upstream side and is subjected to a primary dehydration treatment; and first dehydrated sludge on the rotary disks is fed and discharged from a sludge discharge part located at the most downstream portion of the rotary disks. In the electroosmosis dehydration device, a sludge supply part is provided at the upstream side of an endless filtration fabric spread between rollers.

Abstract: A TIM-3 antibody, an antigen-binding fragment thereof, and medical uses thereof are described. More specifically, the present invention provides a rat-derived antibody containing a CDR region of the TIM-3 antibody, a chimeric antibody or a human-derived antibody thereof, and a pharmaceutical composition containing the TIM-3 antibody and the antigen-binding fragment thereof, as well as uses thereof serving as a drug. In particular, the present invention provides uses of a human-derived TIM-3 antibody in the preparation of drugs for treating TIM-3 -related conditions.

Abstract: Described herein are one or more self-organizing network (SON) components configured to determine QoS factors associated with QoS classes for a node of a telecommunication network based at least in part on performance metrics, network configuration, or network fault information. The one or more SON components may receive the performance metrics, network configuration, or network fault information from the node, and the performance metrics, network configuration, or network fault information may be associated with communication of traffic of the QoS classes by the node. Upon determining the QoS factors, the one or more SON components may transmit indications of the QoS factors to the node.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reduction of resistance to the treatment, prevention, and/or diagnosis of diseases characterized by the formation of cancers. Embodiments include methods of treating cancer, comprising the steps of: providing a patient diagnosed with cancer with a therapeutic regime that includes at least one therapeutically effective dose of at least one agent that reduces the activity of at least one DNA damage/repair pathway. Other embodiments include methods of treating cancer, comprising the steps of: treating a patient diagnosed with cancer with a combination of therapeutic agents that includes at least one therapeutically effective anti-cancer agent and at least one compound that reduces the activity of at least one DNA damage/repair pathway.

Abstract: The present invention discloses a method for the preparation of a protein peptide, peptide powder prepared thereby, and use of the peptide powder in hypouricemic food products or health care products. The peptide powder is capable of inhibiting the activity of xanthine oxidase and effectively reducing uric acid. The method in an example of the present invention comprises: mincing the tuna, heating with steam or water to obtain a pretreated tuna, enzymolyzing the pretreated tuna, deactivating the enzyme, centrifuging, removing impurities to obtain a supernatant, concentrating, and drying to obtain the peptide powder of interest.

Abstract: A drilling rig includes a base section, a first section, a second section, a third section and a fourth section. For the base section upper region, a fixed pulley block and a guide pulley are installed. Except for the fourth section-crown block section, each section lower region is installed with a lifting lug for a movable pulley block installation for substantially vertical lifting. The crown block section is installed substantially vertical; the subsequent section is located substantially horizontal with the section front pillar upper region connecting to the previous section front pillar lower region. The previous section is substantially vertical lifted to draw the next section skidding into the base section and lifting substantially vertical with the previous section pillar lower region connected to the next section pillar upper region. Dismount the movable pulley block from the previous section and installed the movable pulley block with the adjacent section lifting lug.

Abstract: Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-1 or their salts, and methods of treating pain (e.g. chronic pain), or cough or itch disorders using the same.

Abstract: Provided is a method for preparing a reduced titanium powder by a multistage deep reduction, including the following steps of: uniformly mixing a dried titanium dioxide powder with a magnesium powder to obtain a mixture, adding the mixture in a self-propagating reaction furnace, triggering a self-propagating reaction, obtaining an intermediate product of which low-valence titanium oxides TixO are dispersed in an MgO matrix, leaching the intermediate product with a hydrochloric acid as a leaching solution, performing filtering, washing and vacuum drying to obtain a low-valence titanium oxide TixO precursor, uniformly mixing the low-valence titanium oxide TixO precursor with a calcium powder, performing a pressing to obtain semi-finished products, placing the semi-finished products in a vacuum reduction furnace for a second-time deep reduction, and leaching a deep reduction product with a hydrochloric acid as a leaching solution so as to obtain the reduced titanium powder.

Abstract: Disclosed is a turbine rotor device for a gas turbine, the turbine rotor device comprising a turbine rotor body, and a pre-stressed fiber-wound layer, wherein the pre-stressed fiber-wound layer is wound on the periphery of the turbine rotor body to exert a predetermined pre-loading force on the turbine rotor body. Additionally, a rotor, and a gas turbine and a turbine engine having the turbine rotor device are also provided.

Abstract: The invention relates to a method for preparing titanium alloys based on aluminothermic self-propagating gradient reduction and slag-washing refining, and belongs to the technical field of titanium-aluminum alloys. The method comprises the following steps of pre-treating raw materials, weighing the raw materials in the mass ratio of rutile or high-titanium slags or titanium dioxide to aluminum powder to V2O5 powder to CaO to KClO3 being 1.0:(0.60-0.24):(0.042-0.048):(0.12-0.26):(0.22-0.30), performing an aluminothermic self-propagating reaction in a gradient feeding manner to obtain high-temperature melt, performing a gradient reduction melting, performing heat insulation and separating the melt after the feeding is completed, then adding CaF2—CaO—TiO2—V2O5 based refining slags into the high-temperature melt, performing slag washing refining, and finally removing slags to obtain titanium alloys.

Abstract: Disclosed are compounds of Formula A, or a salt thereof: wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

Abstract: A method for ironmaking by smelting reduction in a stir-generated vortex includes: (1) placing a pig iron in an induction furnace, and then heating the pig iron to a molten state to form a molten iron, and maintaining the molten iron to be greater than or equal to 1450° C.; (2) stirring a center of the molten iron to form a vortex with a height-to-diameter ratio of 0.5-2.5, and continuously performing stirring; (3) mixing and grinding on an iron-containing mineral, a reducing agent and a slag-forming agent in a mass ratio of 1:(0.1-0.15):(0.25-0.4) to obtain a powder mixture, spraying and blowing the powder mixture to a center of the vortex, performing a reduction reaction, and stopping the stirring after the molten iron and molten slags are obtained, wherein a waste gas is produced; and (4) discharging the molten iron and the molten slags respectively, and exhausting a treated waste gas.

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.